21

PCT/IL2004/001173

WHAT IS CLAIMED:

WO 2005/062709

- 1. An integrated viral complex, the complex comprising:
- (a) a plurality of intact cell membranes, each of said intact cell membranes belonging to a non-viable cell; and
- (b) a plurality of viable virions, a majority of said virions of said plurality of viable virions contained within said intact cell membrane belonging to said plurality of intact cell membranes.
- 2. The integrated viral complex of claim 1, wherein said virions are DNA virions,
- 3. The integrated viral complex of claim 2, wherein said DNA virions are double stranded DNA virions,
- 4. The integrated viral complex of claim 3, wherein said double stranded DNA virions belong to the herpes viruses.
- 5. The integrated viral complex of claim 4, wherein said herpes virus is Marek's disease virus.
- 6. A pharmaceutical composition for vaccination, the pharmaceutical composition comprising:
- (a) a plurality of intact cell membranes, each of said intact cell membranes belonging to a non-viable cell; and
- (b) a plurality of viable virions, a majority of said virions of said plurality of viable virions contained within said intact cell membrane belonging to said plurality of intact cell membranes; and
 - (c) carriers and excipients.
- 7. The pharmaceutical composition of claim 6, supplied as an article of manufacture including packaging material and instructions for use.

WO 2005/062709

22

PCT/IL2004/001173

- 8. The pharmaceutical composition of claim 6, wherein said virions are DNA virions,
- 9. The pharmaceutical composition of claim 8, wherein said DNA virions are double stranded DNA virions,
- 10. The pharmaceutical composition of claim 9, wherein said double stranded DNA virions belong to the herpes viruses.
- 11. The integrated viral complex of claim 10, wherein said herpes virus is Marek's disease virus.
- 12. A method for producing integrated viral complexes, the method comprising:
 - (a) growing a population of individual cells in culture;
- (b) infecting said individual cells belonging to said population with an aliquot of viable virions so that a desired viral yield is achieved;
- (c) transferring said population of individual cells characterized by said desired viral yield to a storage medium containing a cryoprotectant;
- (d) storing said population of individual cells characterized by said desired viral yield at a temperature in the range of (-) 30 to (+) 8 degrees centigrade.
- 13. The method of claim 12, wherein said infecting employ a viral preparation selected from the group consisting of a cell free preparation and a cell associated preparation.
- 14. The method of claim 12, wherein said cryoprotectant includes at least one material selected from the group consisting of glycerol, DMSO, and sugars.
- 15. The method of claim 12, wherein said desired viral yield is in the range of 0.001 to 1 PFU/cell.

23

PCT/IL2004/001173

- 16. The method of claim 12, wherein said temperature in the range of (+) 2 to (+) 8 degrees centigrade.
 - 17. The method of claim 12, further comprising:

WO 2005/062709

- (e) passaging said individual cells belonging to said population with said desired viral yield as a means of increasing a size of said population.
 - 18. The method of claim 12, further comprising:
- (e) reducing a volume of said storage medium so that a desired number of cells per unit volume is achieved.
 - 19. The method of claim 12, further comprising:
 - (e) drying said population of individual cells.
- 20. A method of producing a pharmaceutical composition for vaccination, the method comprising:
 - (a) growing a population of individual cells in culture;
- (b) infecting said individual cells belonging to said population with an aliquot of viable virions so that a desired viral yield is achieved;
- (c) transferring said population of individual cells characterized by said desired viral yield to a storage medium containing a cryoprotectant;
- (d) dividing said population of individual cells characterized by said desired viral yield into dosage portions suited for vaccination of a specified number of subjects; and
- (e) storing said dosage portions at a temperature in the range of (-) 30 to (+) 8 degrees centigrade.
- 21. The method of claim 20, wherein said dosage portions each individually include a number of doses in the range of 1 to 1 million.

- 22. The method of claim 20, wherein said infecting employ a viral preparation selected from the group consisting of a cell free preparation and a cell associated preparation.
- 23. The method of claim 20, wherein said cryoprotectant includes at least one material selected from the group consisting of glycerol, DMSO, and sugars.
- 24. The method of claim 20, wherein said desired viral yield is in the range of 0.001 to 1 PFU/cell.
- 25. The method of claim 20, wherein said temperature in the range of (+) 2 to (+) 8 degrees centigrade.
 - 26. The method of claim 20, further comprising:
- (f) passaging said individual cells belonging to said population with said desired viral yield as a means of increasing a size of said population.
 - 27. The method of claim 20, further comprising:
- (f) reducing a volume of said storage medium so that a desired number of cells per unit volume is achieved.
 - 28. The method of claim 20, further comprising:
 - (f) drying said population of individual cells.
- 29. A method of vaccination which employs an integrated viral complex, the method comprising administering to a subject at least one dose of an amount of an integrated viral complex sufficient to elicit an active immune response in a subject.
- 30. The method of claim 29, wherein said subject is a member of an avian species.

WO 2005/062709 PCT/IL2004/001173

25

- 31. The method of claim 29, wherein said integrated viral complex includes DNA virions,
- 32. The method of claim 29, wherein said DNA virions are double stranded DNA virions,
- 33. The method of claim 32, wherein said double stranded DNA virions belong to the herpes viruses.
- 34. The method of claim 32, wherein said herpes virus is Marek's disease virus.
- 35. The method of claim 29, wherein said administration is conducted *in* ovo.
- 36. The method of claim 29, wherein said administration is conducted via injection or from 1 day of age.